tetano
Editor, Senior Moderator
FASEB J
. 2023 Jun;37(6):e22973.
doi: 10.1096/fj.202202099RR. Identification of nurse shark V[SUB]NAR[/SUB] single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2
Jesse Buffington[SUP] 1 [/SUP], Zhijian Duan[SUP] 1 [/SUP], Hyung Joon Kwon[SUP] 2 [/SUP], Jessica Hong[SUP] 3 [/SUP], Dan Li[SUP] 3 [/SUP], Mingqian Feng[SUP] 3 [/SUP], Hang Xie[SUP] 2 [/SUP], Mitchell Ho[SUP] 1 3 [/SUP]
Affiliations
SARS-CoV-2 is the etiological agent of the COVID-19 pandemic. Antibody-based therapeutics targeting the spike protein, specifically the S1 subunit or the receptor binding domain (RBD) of SARS-CoV-2, have gained attention due to their clinical efficacy in treating patients diagnosed with COVID-19. An alternative to conventional antibody therapeutics is the use of shark new antigen variable receptor domain (V[SUB]NAR[/SUB] ) antibodies. V[SUB]NAR[/SUB] s are small (<15 kDa) and can reach deep into the pockets or grooves of the target antigen. Here, we have isolated 53 V[SUB]NAR[/SUB] s that bind to the S2 subunit by phage panning from a naïve nurse shark V[SUB]NAR[/SUB] phage display library constructed in our laboratory. Among those binders, S2A9 showed the best neutralization activity against the original pseudotyped SARS-CoV-2 virus. Several binders, including S2A9, showed cross-reactivity against S2 subunits from other β coronaviruses. Furthermore, S2A9 showed neutralization activity against all variants of concern (VOCs) from alpha to omicron (including BA1, BA2, BA4, and BA5) in both pseudovirus and live virus neutralization assays. Our findings suggest that S2A9 could be a promising lead molecule for the development of broadly neutralizing antibodies against SARS-CoV-2 and emerging variants. The nurse shark V[SUB]NAR[/SUB] phage library offers a novel platform that can be used to rapidly isolate single-domain antibodies against emerging viral pathogens.
Keywords: COVID-19; SARS-CoV-2; neutralizing antibody; shark VNAR; single-domain antibody; spike S2 subunit.
. 2023 Jun;37(6):e22973.
doi: 10.1096/fj.202202099RR. Identification of nurse shark V[SUB]NAR[/SUB] single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2
Jesse Buffington[SUP] 1 [/SUP], Zhijian Duan[SUP] 1 [/SUP], Hyung Joon Kwon[SUP] 2 [/SUP], Jessica Hong[SUP] 3 [/SUP], Dan Li[SUP] 3 [/SUP], Mingqian Feng[SUP] 3 [/SUP], Hang Xie[SUP] 2 [/SUP], Mitchell Ho[SUP] 1 3 [/SUP]
Affiliations
- PMID: 37191949
- DOI: 10.1096/fj.202202099RR
SARS-CoV-2 is the etiological agent of the COVID-19 pandemic. Antibody-based therapeutics targeting the spike protein, specifically the S1 subunit or the receptor binding domain (RBD) of SARS-CoV-2, have gained attention due to their clinical efficacy in treating patients diagnosed with COVID-19. An alternative to conventional antibody therapeutics is the use of shark new antigen variable receptor domain (V[SUB]NAR[/SUB] ) antibodies. V[SUB]NAR[/SUB] s are small (<15 kDa) and can reach deep into the pockets or grooves of the target antigen. Here, we have isolated 53 V[SUB]NAR[/SUB] s that bind to the S2 subunit by phage panning from a naïve nurse shark V[SUB]NAR[/SUB] phage display library constructed in our laboratory. Among those binders, S2A9 showed the best neutralization activity against the original pseudotyped SARS-CoV-2 virus. Several binders, including S2A9, showed cross-reactivity against S2 subunits from other β coronaviruses. Furthermore, S2A9 showed neutralization activity against all variants of concern (VOCs) from alpha to omicron (including BA1, BA2, BA4, and BA5) in both pseudovirus and live virus neutralization assays. Our findings suggest that S2A9 could be a promising lead molecule for the development of broadly neutralizing antibodies against SARS-CoV-2 and emerging variants. The nurse shark V[SUB]NAR[/SUB] phage library offers a novel platform that can be used to rapidly isolate single-domain antibodies against emerging viral pathogens.
Keywords: COVID-19; SARS-CoV-2; neutralizing antibody; shark VNAR; single-domain antibody; spike S2 subunit.